All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 164.34 points (-0.9%) at 17,347 as of Wednesday, Aug. 19, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 562 issues advancing vs. 2,422 declining with 143 unchanged.

The Health Care sector as a whole closed the day down 0.8% versus the S&P 500, which was down 0.9%. Top gainers within the Health Care sector included Pingtan Marine Enterprise ( PME), up 3.2%, Skystar Bio-Pharmaceutical ( SKBI), up 2.0%, Jaguar Animal Health ( JAGX), up 3.4%, Cardica ( CRDC), up 5.3% and Dehaier Medical Systems ( DHRM), up 1.7%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the sector higher today:

Dehaier Medical Systems ( DHRM) is one of the companies that pushed the Health Care sector higher today. Dehaier Medical Systems was up $0.03 (1.7%) to $1.84 on light volume. Throughout the day, 3,225 shares of Dehaier Medical Systems exchanged hands as compared to its average daily volume of 28,800 shares. The stock ranged in a price between $1.80-$1.84 after having opened the day at $1.83 as compared to the previous trading day's close of $1.81.

Dehaier Medical Systems has a market cap of $10.6 million and is part of the drugs industry. Shares are down 33.7% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Cardica ( CRDC) was up $0.02 (5.3%) to $0.40 on light volume. Throughout the day, 53,166 shares of Cardica exchanged hands as compared to its average daily volume of 134,000 shares. The stock ranged in a price between $0.38-$0.40 after having opened the day at $0.39 as compared to the previous trading day's close of $0.38.

Cardica, Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. Cardica has a market cap of $32.9 million and is part of the drugs industry. Shares are down 45.7% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates Cardica a buy, no analysts rate it a sell, and 1 rates it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Cardica as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on CRDC go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, CARDICA INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • CRDC's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 65.52%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The revenue fell significantly faster than the industry average of 30.3%. Since the same quarter one year prior, revenues fell by 31.6%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • CRDC's debt-to-equity ratio is very low at 0.13 and is currently below that of the industry average, implying that there has been very successful management of debt levels.
  • CARDICA INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, CARDICA INC continued to lose money by earning -$0.21 versus -$0.32 in the prior year. This year, the market expects an improvement in earnings (-$0.19 versus -$0.21).

You can view the full analysis from the report here: Cardica Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Skystar Bio-Pharmaceutical ( SKBI) was another company that pushed the Health Care sector higher today. Skystar Bio-Pharmaceutical was up $0.03 (2.0%) to $1.46 on light volume. Throughout the day, 880 shares of Skystar Bio-Pharmaceutical exchanged hands as compared to its average daily volume of 21,100 shares. The stock ranged in a price between $1.45-$1.46 after having opened the day at $1.45 as compared to the previous trading day's close of $1.43.

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People's Republic of China. Skystar Bio-Pharmaceutical has a market cap of $12.5 million and is part of the drugs industry. Shares are down 66.1% year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate Skystar Bio-Pharmaceutical a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Skystar Bio-Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from TheStreet Ratings analysis on SKBI go as follows:

  • The revenue growth came in higher than the industry average of 6.8%. Since the same quarter one year prior, revenues rose by 14.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • SKBI's debt-to-equity ratio is very low at 0.16 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.20, which illustrates the ability to avoid short-term cash problems.
  • The gross profit margin for SKYSTAR BIO-PHARMACEUTICAL is rather high; currently it is at 50.16%. Regardless of SKBI's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, SKBI's net profit margin of 26.75% significantly outperformed against the industry.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. When compared to other companies in the Pharmaceuticals industry and the overall market, SKYSTAR BIO-PHARMACEUTICAL's return on equity is below that of both the industry average and the S&P 500.
  • SKBI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 72.98%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

You can view the full analysis from the report here: Skystar Bio-Pharmaceutical Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.